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Available online 21 June 2015AbstractBackground: Quality of Life (QoL) plays an important role in patients with peritoneal metastasis and is deteriorating continuously until
death. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is an innovative palliative treatment of peritoneal metastasis. We present
the first QoL results under PIPAC therapy.
Methods: Retrospective analysis of QLQ30 questionnaire results during repeated courses of PIPAC applications in palliative patients with
pretreated peritoneal metastasis.
Results: 91 patients (M:F ¼ 40:51, median age 64 (34e77) years) with 158 PIPAC applications were analyzed. 86% patients had previously
received systemic chemotherapy. Peritoneal metastasis was advanced (Peritoneal Carcinomatosis Index I ¼ 16  10). At admission, only
moderate impairment of functioning (62e83%) and symptom scores (17e47%) was observed. 48 patients received at least 2 PIPAC every 6
weeks. After PIPAC # 1, the global physical score deteriorated slightly (from 82% to 75%), but improved after PIPAC # 2 (up to 89%).
Gastrointestinal symptoms (nausea/vomiting, constipation, diarrhoea, anorexia) remained stable under PIPAC therapy.
Conclusions: Quality of life was relatively high in this group of patients with advanced, pretreated peritoneal metastasis, explaining their
wish for further therapy. Functioning scores and disease-related symptoms were not altered for at least 3 months in the patients able to
receive repeated PIPAC. Except for a transient moderate increase of pain scores, PIPAC did not cause therapy-related QoL deterioration,
especially no gastrointestinal symptoms.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Peritoneal metastasis is a common pattern in advanced
gynaecological and gastrointestinal cancer with about
167,940 new cases per year in Europe.1 In Germany alone,
about 60 patients are diagnosed with peritoneal metastasisuthor. Department of Surgery, Ruhr University
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).every day, half of them being women with ovarian cancer.
Peritoneal metastasis has a poor prognosis with a median
survival under 6 months and remains an unmet medical
need.2
Palliative systemic chemotherapy is the standard of care
in this situation. However, the efficacy of systemic chemo-
therapy to treat peritoneal metastasis is hampered by
limitations such as poor vascularisation of the peritoneum3
and elevated intratumoral fluid pressure.4 Intraperitoneal
chemotherapy has been increasingly used in peritoneal
metastasis in order to optimize local drug delivery and
improve clinical outcome. Intraperitoneal chemotherapyess article under the CC BY-NC-ND license (http://creativecommons.org/
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neal metastasis as compared to systemic chemotherapy.
However, intraperitoneal chemotherapy is also hampered
by pharmacological limitations such as limited surface
exposition of the peritoneum and poor tissue penetration.5
Side-effects reported after systemic chemotherapy for
peritoneal metastasis are relatively frequent6 and typically
include renal toxicity (cisplatin), neurotoxocity (oxalipla-
tin), and cardiac toxicity (doxorubicin).7e11 Intraperitoneal
chemotherapy is inducing less12 or comparable13 systemic
side-effects but is limited by local toxicity and catheter-
linked complications.
Thus, there is an obvious medical need for better thera-
peutic options in peritoneal metastasis prolonging survival
and preserving QoL by reducing both disease-related symp-
toms and therapy side-effects. Pressurized IntraPeritoneal
Aerosol Chemotherapy (PIPAC) is an innovative drug
delivery system applying chemotherapeutic drugs in
gaseous form under pressure within the closed abdominal
cavity during a laparoscopy. In a large animal model,14,15
ex vivo,16 and in vivo,17 pharmacological properties of
PIPAC have been found to be superior. Specifically, a target
tissue dose of doxorubicine up to 200 higher than
reported after Hyperthermic IntraPeritoneal Chemotherapy
(HIPEC)18 has been documented after PIPAC in the human
patient e with 10% of the dose applied.17
Thus, due to the high local bioavailability during PIPAC,
the chemotherapy dosage can be reduced by one order of
magnitude compared to a usual systemic dose17 which in
turn largely prevents systemic side effects and organ
toxicity.19 Local toxicity is minor and well tolerated. First
evidence for clinical efficacy and safety of PIPAC has
recently been published20,21 and the first prospective
Phase-2 trial has been closed recently.22 PIPAC has been
shown to be safe in the occupational setting.23,24
Here we present the first Quality of Life (QoL) data
obtained in patients with peritoneal metastasis treated
with PIPAC. The aim of the present analysis was to assess
QoL in patients with end-stage peritoneal metastasis. The
second aim was to assess possible changes in QoL before
and after repeated PIPAC applications.
Material and methodsStudy designThis is an observational, retrospective analysis of QoL
data collected routinely in peritoneal metastasis patients
at our institution (registry data).Patients170 patients with advanced peritoneal metastasis were
admitted for PIPAC between 7/2012 and 01/2014 at our
institution (university hospital, tertiary care center). Before
admission, each patient was presented in theinterdisciplinary tumour board and the indication for PI-
PAC was decided on a case-by-case, individual basis.
Bowel obstruction and/or extraperitoneal metastasis were
considered contraindications for PIPAC. Eligible patients
were treated with cytoreductive surgery and HIPEC. Only
patients with platinum-resistant peritoneal metastasis were
treated with PIPAC after application of evidence-based,
guideline-recommended palliative systemic chemotherapy.
The day before the PIPAC procedure, all patients were
invited to fill out the QoL questionnaire, but there was no
obligation to do so.Regulatory frameworkQoL is recorded routinely in all peritoneal metastasis
patients at our institution. PIPAC was applied as off-label
use of approved drugs, according to German legislation.
All patients gave their written informed consent for the
PIPAC procedure and for data collection. The Institutional
Review Board (Ethical Commission of the Ruhr University
Bochum) expressed no objection. Therapy, data collection,
and data analysis were performed according to the Declara-
tion of Helsinki.PIPAC procedureThe PIPAC procedure was performed as follows at 6
weeks intervals. After insufflation of a 12 mmHg CO2
pneumoperitoneum, two balloon safety trocars (5 and
12 mm, Applied Medical, Duesseldorf, Germany) were
inserted into the abdominal wall in an operating room
equipped with laminar airflow. Under video surveillance
the peritoneal metastasis index (PCI) was determined based
on lesion size and distribution.25 Peritoneal biopsies were
taken for histologic confirmation of malignancy during
the first procedure and for ascertainment of tumour regres-
sion during all following procedures. Ascites volume was
documented and ascites was removed. Then, a nebulizer
(MIP, Capnomed GmbH, Villingendorf, Germany) was
connected to an intravenous high-pressure injector (Injek-
tron 82M, MedTron, Saarbruecken, Germany) and was in-
serted into the abdomen. Tightness of the abdomen was
documented via a zero-flow of CO2. A pressurized aerosol
containing cisplatin at a dose of 7.5 mg/m2 body surface in
a 150 ml NaCl 0.9% solution followed by doxorubicin at a
dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% so-
lution were applied via nebulizer and injector. Alterna-
tively, 14 patients with colorectal cancer received
oxaliplatin 92 mg/m2 body surface. Dosage was based on
clinical experience in patients with peritoneal metastasis
treated with PIPAC with documented responses.18,19 Injec-
tion parameters were set at a flow rate of 30 ml/min and a
maximum upstream pressure of 200 psi in the high-pressure
injector. The injection was remote-controlled to exclude
occupational exposure. The therapeutic capnoperitoneum
was maintained for 30 min at a temperature of 37 C.
1381K. Odendahl et al. / EJSO 41 (2015) 1379e1385Then, the chemotherapy aerosol was exsufflated via a
closed line over two sequential microparticle filters into
the airwaste system of the hospital. Finally, trocars were re-
tracted and laparoscopy ended. No drainage of the
abdomen was used.Quality of life assessmentThe study was conducted using the validated EORTC
QLQ C-30 questionnaire26 which was developed to assess
the QoL of cancer patients. It includes 30 different items,
divided into various scales. Specifically, it is split up into
6 scales, containing items for emotional (4 items), social
(2 items) and physical (5 items) functioning, cognitive (2
items) and role (2 items) functioning and further global
health status (2 items). Better function is represented by
higher mean scores in all scales. The questionnaire also
provides symptom scores, including gastrointestinal items
(nausea/vomiting; constipation; diarrhoea; appetite loss)
and pain. Lower scores indicate less symptoms. We choose
a general questionnaire since different drugs were used and
different cancers were pooled.Karnofsky indexThe Karnofsky index (KI)27 was determined systemati-
cally in all cancer patients and was used for estimating
prognosis and defining therapeutic goals. The index scale
ranges from zero (death) to one hundred percent (no
restriction).Table 1
Characteristics of 91 patients treated by Pressurized IntraPeritonealFollow-up
Aerosol Chemotherapy (PIPAC) for advanced peritoneal carcinomatosis.
All patients
(n ¼ 91)
Patients with 2
PIPAC (n ¼ 48)Patients were followed-up until July 31st, 2014 or until
death.n % n %
GenderStatistical analysis
Females 51 56% 25 52%
Males 40 44% 23 48%
Age
Median (minemax) 60 (34e77) 58 (37e77)
Karnofsky Index
Mean (SD) 84 (14) 86 (13)
Previous therapy
Time from cancer diagnosis
(months, mean  SD)
23 (26) 22 (27)
Previous systemic chemotherapy 78 86% 40 83%
Extent of peritoneal
carcinomatosis
Peritoneal carcinomatosis index
(mean  SD)
16 (10) 15 (9)
Cancer origin
Ovarian 25 27% 8 15%
Stomach 29 32% 18 38%
Colorectal 14 15% 8 19%
Appendix 6 7% 4 6%
Mesothelioma 4 4% 1 6%
CUP 6 7% 5 8%
others 7 8% 4 8%For statistical analysis, the EORTC QLQ-30 scores were
linearly converted to a 0e100 scale according to EORTC
recommendations.28 Missing items were imputed for the
EORTC QLQ-C30, using the method advocated by the
EORTC QoL research Group. A moderate change of
10e20 points was considered clinically significant. Statis-
tics were performed using the SPSS version 14.0 software.
Descriptive statistics included mean, median, percentiles,
and confidence interval. Data are presented as line charts.
No comparative statistics are provided.
Results
To assess Quality of Life (QoL) in patients with
advanced peritoneal metastasis, we reviewed the protocols
of 114 consecutive patients having received at least 2 PIPAC
within the period of time under investigation. Ninety-one
patients filled out at least one QoL questionnaire and 48patients filled out at least 2 QoL questionnaires. Patients’
characteristics are summarized in Table 1.
QoL results are divided into two parts as follows: first,
QoL data obtained in patients with advanced peritoneal
metastasis are presented; second, evolution of QoL data
under PIPAC therapy are evaluated.QoL in patients with end-stage peritoneal metastasisThe first specific question of the present analysis was to
assess QoL in patients with advanced, platinum-resistant
peritoneal metastasis. 78/91 patients (86%) had received
previous palliative systemic chemotherapy, and the mean
time since cancer diagnosis was 23 (26) months. Mean
Karnofsky index was 86 (14) %, with 11 patients with
Karnofsky < 70%. Thus, it is apparent that patients had
late-stage metastatic disease. Median survival after the first
PIPAC application was 13.4 months with a mean follow-
up of 12.0 months. The actuarial survival curve is given in
Fig. 1.
EORTC QLQ-30 functioning and symptom scores were
determined at admission and were found to be moderately
altered. These scores are detailed in Table 2. For example,
the physical functional (PF) score was 75%  28%.
In earlier studies, cancer patients were grouped accord-
ing to time from first assessment to death in order to
explore the association between QoL scores and survival.29
We applied the same method in patients with peritoneal
months
3024181260
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Figure 1. Survival curve of 91 patients with platin-resistant peritoneal
carcinomatosis treated with Pressurized IntraPeritoneal Aerosol Chemo-
therapy (PIPAC). Median survival was 13.4 months.
n
d
in
a
g
en
er
al
p
o
p
ul
at
io
n
o
f
p
at
ie
n
ts
w
it
h
ad
va
n
ce
d
ca
n
ce
r.
2
5
P
F
:
P
h
y
si
ca
l
fu
n
ct
io
ni
n
g.
E
F
:
N
V
:
N
au
se
a/
V
o
m
it
in
g
sc
o
re
.
PA
:
P
ai
n
sc
o
re
.
D
I:
D
ia
rr
h
o
ea
sc
o
re
.
D
Y
:
D
y
sp
n
o
ea
sc
o
re
.
A
P
:
S
y
m
pt
o
m
s
e
si
ng
le
it
em
s
PA
m
ea
n
D
I
m
ea
n
D
Y
m
ea
n
A
P
m
ea
n
S
L
m
ea
n
C
O
m
ea
n
F
I
m
ea
n
4
8

3
6
2
6

3
4
3
9

3
6
5
1

3
9
4
0

3
1
4
3

3
9
1
6

2
7
3
5

3
0
1
9

2
8
2
6

3
0
3
1

3
3
3
3

3
1
1
7

2
9
2
0

3
0
1382 K. Odendahl et al. / EJSO 41 (2015) 1379e1385metastasis and found a continuous deterioration in most
functional and symptom scales during the last months of
life. These data are summarized in Fig. 2 (panel a) and
Fig. 3 (panel a).at
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were in relationship with PIPAC (2 iatrogenic bowel access
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progression (small bowel obstruction, refractory ascites).
One (1%) adverse event CTCAE 4 (anaphylactic shock
after intraoperative metamizol injection) and 8 (8.8%)
adverse events CTCAE 3 were recorded (liver toxicity:
n ¼ 4; abdominal pain: n ¼ 2; cholangitis (obstruction of
a biliary stent)): n ¼ 1: ileus ¼ 1. Secondary access was
not possible in 5 patients (5.5%) due to adhesions or
disease progression.[%
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7The second specific question was to assess the evolution
of QoL during therapy. For this purpose, we analyzed the
records of the 48 patients having received at last 2 PIPAC
applications. Functional scores, including physical,
emotional, cognitive, role and social scores are illustrated
in Fig. 2b. There was no further deterioration of the scores
in the patients receiving repeated PIPAC applications over a
period of 3 months. The evolution of gastrointestinal symp-
tom scores, including nausea/vomiting, appetite loss, obsti-
pation, and diarrhoea is illustrated in Fig. 3b. In analogy to
the functional scores, the gastrointestinal scores remained
largely constant during the observation period. Pain score
deteriorated slightly after PIPAC # 1 (from 28% to 37%),
Figure 2. EORTC-QLQ30 functional scores. Left panel: in 91 peritoneal carcinomatosis patients classified according to their survival at time of assessment;
right panel: in a subgroup of 48 of those patients having received at least 2 PIPAC at 6 weeks intervals. X-axis: days until death. Y-axis: score in %.
Figure 3. EORTC-QLQ30 symptom scores. Left panel: in 91 peritoneal carcinomatosis patients classified according to their survival at time of assessment;
right panel: in a subgroup of 48 of those patients having received at least 2 PIPAC at 6 weeks intervals. X-axis: days until death. Y-axis: score in %.
1383K. Odendahl et al. / EJSO 41 (2015) 1379e1385but then improved again (32%). When contrasted with Figs.
2a and 3b, these data demonstrate a stabilization of QoL in
peritoneal metastasis patients receiving repeated PIPAC
applications.
Discussion
Declining quality of life scores with physical deteriora-
tion prior to death has already been documented in cancer
patients.29,30 Disease progression induces a rapid and
continuous deterioration of quality of life. Response to sec-
ond or subsequent lines of chemotherapy is strongly influ-
enced by response to earlier treatment; patients with no
response to up to two initial lines of treatment are less
likely to respond to a third or subsequent line. For example,in gastric cancer, benefit of second-line combination
chemotherapy schemas seems to be limited to patients
with a good performance status, and treatment toxicity
and discomfort are substantial, in particular with regimens
containing cisplatin and infusional 5-FU.6 In patients with
advanced colorectal cancer under symptomatic therapy,
the mean QLQ-30 physical performance deteriorated by
8.6 points at eight weeks and by 12.5 points at 16 weeks.
Similarly, the global health score deteriorated by 7.1 points
at eight weeks and by 15.2 points at 16 weeks.31
Many patients with advanced, platin-resistant peritoneal
metastasis have still a relatively good performance status,
and their gastrointestinal symptoms are moderate. Their
hope for continued, high-quality life leads them to seek
treatment beyond the standard of care, such as PIPAC.
1384 K. Odendahl et al. / EJSO 41 (2015) 1379e1385Scores documented in our study are in good agreement with
those determined in advanced cancer patients with a life
expectation of >4 months29 and with long-time survivors
after cytoreductive surgery and HIPEC for peritoneal
metastasis.32
PIPAC is a novel drug delivery system in the therapy of
peritoneal metastasis in the salvage situation which
optimizes physical conditions (gaseous nature and artificial
hydrostatic pressure) to improve the pharmacology of drug
delivery into the peritoneal tumour nodules, allowing a
significant dose reduction (reviewed in33). The first Phase-
2 trial with low-dose PIPAC with cisplatin 7.5 mg/m2 and
doxorubicin 1.5 mg/m2 body surface in recurrent, platin-
resistant ovarian cancer showed a clinical benefit rate of
60% in the third-line situation.22 Safety data were encour-
aging with no CTCAE grade 4 and 5 events, grade 3 events
only 15% of patients. Local toxicity of PIPAC on the bowel
was well controlled (no perforation), liver and renal toxic-
ities were minimal19 and systemic side-effects were rare.34
We now report the first QoL results obtained in patients
with peritoneal metastasis in the salvage situation treated
with PIPAC. QoL was assessed before starting PIPAC and
over a period of 3 months during the course of treatment.
The most striking result that emerges from this study is
the stabilisation of QoL under PIPAC. Functional scores
remained stable, and gastrointestinal symptoms did not
deteriorate under therapy. Only pain scores increased
slightly and this negative effect was transitory. Transient
abdominal pain might be explained by the chemical perito-
nitis induced by PIPAC. Classical side-effects of systemic
chemotherapy such as mucositis, nausea/vomiting, diar-
rhoea, paraesthesia, cutaneous symptoms and alopecia
were not reported by the patients.
To determine if a new treatment is clinically meaningful
in the palliative situation, tolerability of treatment-related
toxicities is of critical importance. If a therapy is less toxic
than prevailing treatments, a smaller improvement in effi-
cacy is acceptable. Conversely, a highly toxic therapy
should be accompanied by an expectation of substantially
greater benefit to provide a clinically meaningful outcome.35
In this context, the results obtained with PIPAC in this
first cohort of palliative patients with platin-resistant perito-
neal metastasis appear encouraging. This study provides first
evidence that PIPAC does not alter quality of life of perito-
neal metastasis patients in the salvage situation. However,
these results should be considered with caution. First, this
is a retrospective study. There was a self-selection bias
because the most affected patients were excluded e patients
who feel bad are lost to follow-up and do not fill out the
questionnaire anymore.
Secondly, QoL remained stable under PIPAC therapy but
this was only true in patients able to receive this therapy. In
particular, 5 patients (5.5%) having experienced severe
adverse events (CTCAE 3 to 5) after PIPAC did not receive
further therapy, which might be a bias. Thus, extrapolation
of these results to other patients with peritoneal metastasisis not possible. Moreover, it is unclear if the stabilization of
symptoms observed was due to disease control or to the
relief of side-effects previously induced by systemic
chemotherapy. Finally, we could not determine how long
quality of life remains stable under PIPAC therapy, and
which proportion of patients truly benefit of this therapy.
QoL is difficult to measure and interpret, even when
using validated instruments such as the QLQ30 question-
naire. Numbers reported here cannot be directly compared
with numbers reported after systemic chemotherapy, or
with patients who did not receive PIPAC in this challenging
clinical setting: the patients treated with PIPAC had
advanced disease, 11 of them having a Karnofsky Index
lower than 70%, 24 more than 1000 ml ascites and 22 a
Peritoneal Carcinomatosis Index (PCI) superior to 25.
Although indication for PIPAC was decided on an individ-
ual basis by our interdisciplinary tumour board and no
inclusion and exclusion criteria were predefined, there
was some selection since patients with bowel obstruction
or distant organ metastases were not treated.
Further work could for example include a long term lon-
gitudinal prospective study on QoL of patients with perito-
neal metastasis treated with systemic chemotherapy and
then with PIPAC, if possible from the time point of
diagnosis of peritoneal metastasis. Such a study design
would adequately describe the evolution of specific symp-
toms along the course of disease. It would also allow a
direct comparison of the evolution of QoL under systemic
chemotherapy and under PIPAC, each patient being his
own control. Randomized delayed comparison with
patients who do not receive PIPAC immediately in this
palliative care setting may also be of use.36 The rationale
for such a prospective study is now given, since PIPAC
holds promise to stabilize QoL of peritoneal metastasis
patients in the salvage situation, for a period of time that
remains to be determined.
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